Oct 04 2021
NEW YORK, New York – EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the promotion of senior executives of their investment team.
• Brooks Andrews has been promoted to Managing Director; and
• Shaunak Parikh has been promoted to Managing Director
In addition, Ron Eastman will assume the role of Senior Advisor after serving as Managing Director since 2006.
Scott Barry, who heads the EW New York office, commented “Brooks and Shaunak have played a key role in several of EW’s successful growth equity investments and become highly-respected and value-added partners to our portfolio company CEOs, management teams and boards as they build rapidly growing companies in the pharma, medtech and technology-enabled healthcare service sectors. Their hands-on, highly collaborative and long-term oriented approach has contributed significantly to the success of many of EW’s investments.”
Brooks joined EW in 2013, after working at FFL Partners (“FFL”), a growth-oriented private equity firm focused on business and healthcare services, based in San Francisco. At FFL, he worked on several healthcare services investments including IT, dental, practice management, and urgent care. Prior to FFL, Brooks worked at Barclay’s Capital in the firm’s investment banking division, focusing on financings, mergers, and acquisitions in the communications and media industries.
Brooks currently plays a key role in EW investments in Sonendo, Xenex, and EyePoint Pharmaceuticals (NASDAQ: EYPT). In addition, he has previously been a key contributor to several of EW’s other growth equity investments including Axogen (NASDAQ: AXGN), Corium (acquired by Gurnet Point), and ProteinSimple (acquired by BioTechne).
Brooks received his Bachelor of Business Administration degrees in Economics and Finance, and a Master of Arts degree in Economics from the University of Georgia, and a Master of Business Administration degree from Stanford University.
Shaunak also joined EW in 2013, after working as an investor at Health Evolution Partners, a private equity firm focused on healthcare growth equity and buyout investments. Previously, he worked in the investment banking group at Citigroup, where he focused on mergers and acquisitions, primarily in the medical device and pharmaceutical sectors.
Shaunak currently plays a key role in EW’s investments in TissueTech and Prolacta. In addition, he has previously been a key contributor to several of EW’s other growth equity investments including Cardiva (acquired by Haemonetics), Bioventus (NASDAQ: BVS) and Tela Bio (NASDAQ: TELA).
Shaunak earned his Master of Business Administration degree from The Wharton School at the University of Pennsylvania and graduated Phi Beta Kappa and with Honors from the University of California, Los Angeles with a Bachelor of Science degree in Microbiology, Immunology and Molecular Genetics and a Bachelor of Arts degree in Economics.
“We are pleased to welcome Brooks and Shaunak to our team of Managing Directors. They have proven their ability to source and lead attractive healthcare growth equity investments and help the CEOs and management teams of innovative healthcare companies drive the growth of their businesses,” said Dr. Petri Vainio, Chairman of the EW Executive Committee.
About EW Healthcare Partners
EW Healthcare Partners is one of the largest and oldest private healthcare investment firms and seeks to make growth equity investments in fast growing commercial-stage healthcare companies in the pharmaceutical, medtech, and technology-enable services sectors in the United States and in Europe. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of over 20 investment professionals with offices in Houston, New York and London. For more information, see www.ewhealthcare.com